About Kawin

POSITION:Home>About Kawin>Milestones


  • 2018
    • Peginterferon alfacon-2 Injection approved by NMPA
    • NDA Submission of coblopasvir
    • Ukrainian GMP recertification of manufacture facility at No.7 Rongchang Street east
    • GMP recertification of multiple products and formulations
    • National High-tech Enterprise recertification
  • 2017
    • Submission of the first China’s generic sofosbuvir tablet for ANDA
    • Submission of generic pirfenidone tablet for ANDA
    • Strategic partnership with Gaolin Capital
    • Designation of Beijing BDA Innovation Workshop
    • GMP recertification of multiple formulations at No. 7 Rongchang Street East site
  • 2016
    • Dr. Zhou Desheng enrolled in the second batch of the national "Million Talents Plan".
    • China's first generic sofosbuvir raw materials and tablets were granted clinical trial approval.
    • The investigative new drug KW-136 with independent intellectual property rights granted CTA.
    • Established “Beijing Municipal Engineering Laboratory of Liver Disease Therapeutic Drug Research”.
    • Enrolled in the first batch of the 13th Five-Year Plan "Beijing Biopharmaceutical Industry Breakthrough Development Project (G20 Project)".
  • 2015
    • Dr. Zhou Desheng was nominated as Innovative Entrepreneurial Talent of Ministry of Science and Technology of the People’s Republic of China.
    • Certified by Colombian INVIMA GMP.
    • Introduced Eli Lilly Strategic Investment.
    • Invested GinkgoPharma(Suzhou)Co., Ltd.
  • 2014
    • Certified as "Beijing Patent Demonstration Unit".
    • Be the first sponsor of generic Sofosbuvir trial in China.
    • Applied an IND for KW-136 with independent intellectual property rights.
    • Selected as "Beijing Biomedical Industry Crossing Development Project (G20 Project)".
    • Enrolled in "Beijing Biopharmaceutical Industry Breakthrough Development Project(G20 Project)".
    • Established "Beijing municipal International Scientific & Technological collabration Base –Preventative & Therapeutic New Drug of Liver Disease."
  • 2013
    • Dr. Hai Pan, VP of R&D, was nominated as China’s national “Recruitment Plan of Global Experts”, a prestigious program for overseas talents.
    • Launched a new product– recombinant human interferon alfa-2b effervescent tablet, China’s first-ever commercialized interferon product in this dosage form.
  • 2012
    • Formed a strategic partnership with Haitong Capital and Cybernaut.
    • Initiated the construction of a brand new 2000-sqm pilot production center.